Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis
Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis
复制标题
DOI：
10.1111/liv.13551
复制
发表时间：
2018-02-01
影响因子：
6.7
通讯作者：
Such, Jose
中科院分区：
文献类型：
--
作者：
Gomez-Hurtado, Isabel;Gimenez, Paula;Such, Jose
背景与目的：诺氟沙星用于预防肝硬变患者的细菌感染是有效的，但与耐药菌的产生有关。众所周知，利福昔明在肠道中的浓度很高，而不会在肠道菌群中产生相关的耐药性。我们的目的是比较诺氟沙星和利福昔明对肝硬变大鼠肠道菌群组成、细菌移位和存活的影响。动物分为3组：单纯CCl_4组(n=10)、CCl_4+诺氟沙星组(n=17)和CCl_4+利福昔明组(n=14)。检测肠道细菌组成、细菌易位和细胞因子水平。结果：最终纳入41只大鼠。在接受诺氟沙星治疗的动物中，活和非活细菌易位的发生率显著降低；利福昔明也降低了活和非活细菌易位的发生率，但没有达到统计学意义。抗菌素组血清肿瘤坏死因子-α水平显著降低。结论：诺氟沙星比利福昔明能更有效地预防肝硬变大鼠肠道细菌移位，其机制可能与诺氟沙星减少肠道微生物区系的致病菌有关。
Background & Aims: Norfloxacin administration is useful in preventing bacterial infections in cirrhosis but associated to the generation of resistant species. Rifaximin is known to reach high concentrations in the intestinal lumen without generating relevant resistance in the intestinal flora. Our aim was to compare the effect of Norfloxacin and Rifaximin on intestinal flora composition, bacterial translocation and survival in cirrhotic rats.Methods: Cirrhosis was induced in rats by oral administration of CCl4. Animals were divided into three groups: only CCl4 (group I, n = 10); CCl4 + Norfloxacin (group II, n = 17) and CCl4 + Rifaximin (group III, n = 14). Gut bacterial composition, bacterial translocation and cytokine levels were measured.Results: Forty-one rats were finally included. The incidence of viable and non-viable bacterial translocation was significantly reduced in animals receiving Norfloxacin; Rifaximin also decreased the incidence of viable and non-viable bacterial translocation, but did not reach statistical significance. Serum TNF-alpha levels were significantly lower in antibiotic groups. Norfloxacin modified intestinal microbiota, depleting significantly more pathobionts than Rifaximin.Conclusion: Norfloxacin is more effective than Rifaximin in preventing bacterial translocation in rats with cirrhosis probably because of its capacity to reduce pathobionts from intestinal microbiota.